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Abstract
Background: As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer
(ROC) where treatment options for advanced disease are still limited. Cardiac safety
for trabectedin monotherapy (T) for STS or in combination with pegylated liposomal
doxorubicin (T+PLD) for ROC was evaluated in this retrospective postmarketing
regulatory commitment.
Methods: Patient data for multiple cardiac-related treatment-emergent adverse events
(cTEAEs) were evaluated in pooled analyses of ten phase 2 trials, one phase 3 trial in
STS (n = 982), and two phase 3 trials in ROC (n = 1231).
Results: Multivariate analyses on pooled trabectedin data revealed that cardiovascular medical history (risk ratio [RR (95% CI)]: 1.90 [1.24-2.91]; p = 0.003) and
age ≥65 years (RR [95% CI]: 1.78 [1.12-2.83]; p = 0.014) were associated with increased risk for cTEAEs. Multivariate analyses showed increased risk of experiencing
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cTEAEs with T+PLD compared to PLD monotherapy (RR [95% CI]: 2.70 [1.75-
4.17]; p < 0.0001) and with history of prior cardiac medication (RR [95% CI]: 1.88
[1.16-3.05]; p = 0.010).
Conclusions: For patients with STS or ROC who still have limited treatment options,
trabectedin may be initiated after carefully considering benefit versus risk.
Trial Registration (ClinicalTrials.gov): NCT01343277; NCT00113607; NCT018
46611.
KEYWORDS

anthracycline, cardiac toxicity, chemotherapy, patient outcomes, soft tissue sarcomas
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IN T RO D U C T IO N

Trabectedin is a DNA-binding agent with a unique antitumor
mechanism of action (MOA) targeting the transcription-coupled
nucleotide excision repair (NER) system. Trabectedin was developed for the treatment of soft tissue sarcomas (STS) and
epithelial ovarian cancer based on its novel cytotoxic activity.
These cancers still have limited treatment options, particularly
where advanced disease has progressed with other therapies.1
Preclinical studies with trabectedin showed no toxicity in
cultured rat myocytes in vitro, while single and repeated doses
in Cynomolgus monkeys did not induce any relevant cardiac,
vascular, or respiratory effects.2 Further, a low incidence of
cardiac-related treatment-emergent adverse events (cTEAE)
was reported in previous analyses from earlier phase 1–2 clinical trials and one phase 3 (OVA-301), pharmacovigilance
databases, and spontaneously reported cases; tachycardia or
palpitations were the most common cTEAEs reported.2 No
clinically relevant left ventricular ejection fraction (LVEF)
changes occurred in phase 1 combination trials, while LVEF
decreases from baseline were similar [9% of patients (pegylated liposomal doxorubicin [PLD]) and 7% (trabectedin+PLD)] with no relevant symptoms in one phase 3 trial.2
Trabectedin is now approved for STS in 80 countries
and for ovarian cancer in combination with PLD in 71
countries. European Union (EU) approval for trabectedin+PLD for relapsed platinum-sensitive ovarian cancer was
granted in October 2009. In the United States (US), trabectedin was approved for STS treatment following the failure of anthracycline-based chemotherapy in October 2015.
Approval in the United States was contingent upon undertaking post-marketing requirements to characterize risk of
cardiotoxicity and its sequelae with trabectedin to identify
risk factors including previous treatments known to be cardiotoxic (e.g., anthracyclines).
As an extension to the cTEAE analysis reported in 20112,
we now report the findings of this retrospective pooled analysis of key cTEAEs for all patients enrolled in ten phase 2 trials and one phase 3 trial involving trabectedin monotherapy

(T) for STS and other solid tumors and two phase 3 trials in
combination with PLD for recurrent ovarian cancer (ROC).

2

|

M ETHODS

2.1 | Overall safety evaluation plan and
description of safety studies
Safety analysis sets incorporated two pooled analyses:
Cardiac safety with T was evaluated using data from ten
phase 2 and one phase 3 trial (SAR-3007 [NCT01343277]) in
STS and other solid tumors at a dose and regimen of 1.5 mg/
m2 every 3 weeks (q3wk), 24 h. Cardiac safety with combination trabectedin+PLD was derived from two phase 3 ovarian cancer trials (OVA-301 [NCT00113607] and OVC-3006
[NCT01846611]) where trabectedin (1.1 mg/m2 q3wk; 3 h)
was co-administered with PLD (30 mg/m2 q3wk; 90 min).
Phase 3 trial designs are described in Table 1. Key inclusion/exclusion criteria for enrollment are presented for each
phase 3 trial (Table S1), cardiac safety evaluations by individual trial (Table S2), and exposure and cancer diagnoses
for pooled data from phase 2 and 3 studies (Table S3). Study
protocols and amendments were reviewed by an Independent
Ethics Committee or an Institutional Review Board.

2.2

|

Statistical methodology

2.2.1 | Definition of subgroups and general
analysis methods
Continuous variables were summarized using descriptive
statistics (i.e., mean, standard deviation [SD], median, and
range) and categorical variables by frequency counts and percentages. Time-to-event variable data were summarized by
Kaplan-Meier methods for 25th, 50th, and 75th percentiles
with 95% confidence intervals (CIs). Treatment group comparisons are presented by hazard ratios and 95% CI from Cox
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Overview of study designs for phase 3 trials

Protocol

Study description

Treatment groups

Patients in safety
analysis set, n

Phase 3 soft tissue sarcoma study –single-agent therapy
SAR-3007 (NCT01343277)

A multicenter, open-label, randomized,
active-controlled, parallel-group phase 3
study comparing the safety and efficacy
of trabectedin versus dacarbazine
among adults with unresectable, locally
advanced or metastatic L-sarcoma,
previously treated with at least an
anthracycline and ifosfamide-containing
regimen or an anthracycline-containing
regimen and one additional cytotoxic
chemotherapy regimen. A normal
LVEF at baseline was not required for
enrollment.

Trabectedin Arm: 1.5 mg/m2 as a 24 h
IV infusion q3wk.

378

Dacarbazine Arm: 1 g/m2 as a 20-to
120-min IV infusion q3wk.

172

Trabectedin+PLD Arm: PLD,
30 mg/m2 as a 90-min infusion
immediately followed by a 3 h
trabectedin IV infusion 1.1 mg/m2
q3wk.

333

PLD Arm: PLD, 50 mg/m2 as a 90-
min infusion q4wk.

330

Treatment Arm A: PLD 30 mg/m2 as
a 90-min infusion immediately
followed by a 3 h trabectedin
infusion 1.1 mg/m2 q3wk.

286

Treatment Arm B: PLD, 50 mg/m2 as
a 90-min infusion q4wk.

282

Phase 3 ovarian cancer studies –combination therapy
OVA-301 (NCT00113607)

OVC-3006 (NCT01846611)

A multicenter, open-label, randomized
study to assess the safety and efficacy
of trabectedin+PLD versus PLD in
patients with ROC treated with only one
platinum-based chemotherapy regimen.
Patients with a normal LVEF at baseline
were eligible to enroll in the study.
A multicenter, open-label, randomized
study to assess the efficacy and
safety of trabectedin+PLD as third
line chemotherapy in patients with
platinum-sensitive ROC who received
two previous lines of platinum-based
chemotherapy. Patients with a normal
LVEF at baseline were eligible to enroll
in the study.

Abbreviations: IV, intravenous; L-sarcoma, leiomyosarcoma or liposarcoma; LVEF, left ventricular ejection fraction; PLD, pegylated liposomal doxorubicin; q3wk,
once every 3 weeks; q4wk, once every 4 weeks; ROC, recurrent ovarian cancer.

proportional hazards models. Anthracycline exposure data
are summarized for subjects who received anthracyclines
prior to the study (i.e., prior anthracycline) and for subjects
who received anthracyclines prior to and during the study
(i.e., cumulative anthracycline).
Two parameters were used for the cardiac safety analysis:
LVEF significant decline where available and cardiac-related
AEs of special interest (cardiac-related AEs). Cross tabulation of ECG data were included when available.

2.2.2

|

Cardiac-related adverse events

cTEAEs are summarized from time of first administration
to 30 days after the last dose and graded using Common
Terminology Criteria for Adverse Events (CTCAE; version 4.0). Incidences of cTEAEs are defined by eight Medical
Dictionary for Regulatory Activities (MedDRA) high-level

group terms (HLGTs) and associated preferred terms (PTs)
and two Standardized MedDRA Queries (narrow SMQ)
(Table 2). HLGTs included cardiac and vascular investigations (excluding enzyme tests), cardiac arrhythmias, cardiac
disorder signs and symptoms, coronary artery disorders, endocardial disorders, heart failures, myocardial disorders, and
pericardial disorders. TEAEs were coded to MedDRA version
16.0 for OVA-301, SAR-3007, and pooled safety analysis for
T. TEAEs in OVA-301 were aligned to MedDRA version
19.0 to match the MedDRA version of OVC-3006 and cTEAEs presented by HLGTs and SMQs and related PTs.

2.2.3

|

Left ventricular ejection fraction

LVEF significant decline was defined as absolute decrease
≥15%, or <lower limit of normal and absolute decrease ≥5%.
LVEF recovery for subjects with significant LVEF decline

|
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cTEAEs
HLGT

Cardiac and vascular investigations (excluding enzyme tests)
Cardiac arrhythmias

T A B L E 2 MedDRA HLGT and
standardized MedDRA queries (narrow
SMQ)

Cardiac disorder signs and symptoms
Coronary artery disorders
Endocardial disorders
Heart failure
Myocardial disorders
Pericardial disorders
SMQ

Cardiac failure
Cardiomyopathy

Abbreviations: cTEAEs, cardiac-related treatment-emergent adverse events; HLGT, high-level group term;
MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized MedDRA query.

T A B L E 3 Number of patients exposed to study treatment and
safety analysis sets
Study

No. patients in safety analysis set

Monotherapy

Trabectedin

Dacarbazine

SAR-3007

378

172

10 phase 2 Studies

604

–

Pooled Data (SAR-
3007+phase 2
Studies)

982

–

Trabectedin+PLD

PLD

OVA-301

333

330

OVC-3006

286

282

Pooled Data (OVA-
301+OVC-3006)

619

612

Combination Therapy

Abbreviation: PLD, pegylated liposomal doxorubicin.

was defined as either return to baseline values or <Grade
2 ejection fraction decreased toxicity (CTCAE v4.0). In
all three phase 3 studies (SAR-3007, OVA-301, and OVC-
3006), LVEF assessments were performed at baseline and
end of treatment. Additionally, OVC-3006 was amended to
provide comprehensive cardiac evaluations of patients while
on treatment. Collection time points for LVEF in each study
are described in Table S2.

3
3.1

|

R E S U LTS

|

Overall exposure

Table 3 shows the number of patients exposed to study
drug by individual trial and by pooled safety analysis sets
for T and trabectedin+PLD. Nine hundred and eighty-two

patients were exposed to T, and 619 patients were treated
with trabectedin+PLD.

3.2 | Baseline characteristics: trabectedin
monotherapy (T)
3.2.1

|

Demographic characteristics

Patients treated with trabectedin (N = 982) had a median
(range) age of 54 (12–
81) years (Table S4). Most patients were female (61.6%), white (50.6%), from North
America (58.2%) or Western Europe (36.7%), had an
Eastern Cooperative Oncology Group performance score
of 0 or 1 (99.8%), and a diagnosis of STS (88.0%). Prior
anthracycline use was reported for 71.3% (Table 4).
Prior anthracycline dose was only captured in the phase
3 SAR-3007 study. A cumulative dose of prior anthracycline was reported for 337/378 subjects in the trabectedin
treatment group and 162/172 subjects in the dacarbazine
group. Median cumulative prior anthracycline dose was
270.00 mg/m2 in the trabectedin group and 240.75 mg/m2
in the dacarbazine group.

3.2.2

|

Cardiovascular medical history

Pooled analyses of T, cardiovascular medical history categorized under the vascular disorder and/or cardiac disorder
system organ class (SOC) was reported for 355 (36.2%) of
982 trabectedin-treated patients. The most commonly reported cardiovascular medical history for patients treated
with trabectedin were hypertension (24.8% [244/982]),
followed by deep vein thrombosis (2.9% [28/982]), hot
flush (2.2% [22/982]), and coronary artery disease (2.1%
[21/982]).
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T A B L E 4 Disease characteristics for patients treated with
trabectedin 1.5 mg/m2 q3wk; 24 h (trabectedin -pooled phase 2 and 3
studies)

Number (%)

Patients treated
with trabectedin
1.5 mg/m2 q3wk;
24 h (N = 982)

Cancer type
STS, L-type

661 (67.3)

STS, Non-L-type

203 (20.7)

Ovarian

54 (5.5)

Breast

26 (2.6)

Renal

21 (2.1)

Melanoma

12 (1.2)

Prostate

5 (0.5)

Prior anthracycline treatment

700 (71.3)

Data are presented as No. (%).
Abbreviations: L-type, leiomyosarcoma or liposarcoma; STS, soft tissue
sarcomas; q3wk, once every 3 weeks.

3.3 | Baseline characteristics: trabectedin in
combination with PLD
3.3.1

|

Demographic characteristics

In the pooled analysis of trabectedin+PLD, patient demographic characteristics were consistent in the all-
female study populations across the trabectedin+PLD
(N = 619) and PLD monotherapy (N = 612) groups, with
median (range) ages of 58 (26–8 3) and 59 (27–9 1) years,
respectively. Most patients were white (84% and 82%,
respectively) (Table S5), and baseline disease characteristics were consistent across both treatment groups
(Table 5).

3.3.2

|

Cardiovascular medical history

In pooled analysis of trabectedin+PLD, 45.6% and 51.5%
of patients in the trabectedin+PLD and PLD monotherapy
groups, respectively, had prior cardiovascular medical history reported for vascular and/or cardiac disorders SOC.
These included: hypertension (30.5% [189/619] in the
trabectedin+PLD group and 34.6% [212/612] in the PLD
monotherapy group), followed by myocardial ischemia
(6.0% [37/619] and 6.7% [41/612], respectively), varicose
vein (3.9% [24/619] and 3.8% [23/612], respectively), deep
vein thrombosis (2.7% [17/619] and 2.5% [15/612], respectively), and hot flush (1.8% [11/619] and 2.9% [18/612],
respectively).

|
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T A B L E 5 Disease characteristics at baseline for treated patients
(pooled studies ET743-OVC-3006 and ET743-OVA-301 studies)
Number (%)

Trabectedin+PLD
(N = 619)

PLD (N = 612)

Histology
Papillary/Serous

412 (66.6)

420 (68.6)

Other

97 (15.7)

92 (15.0)

Endometrioid

38 (6.1)

37 (6.0)

Clear Cell
Carcinoma

24 (3.9)

21 (3.4)

Peritoneal
Carcinoma

21 (3.4)

17 (2.8)

Fallopian Tube
Carcinoma

10 (1.6)

15 (2.5)

Mixed Epithelial
Tumor

7 (1.1)

5 (0.8)

Mucinous
(exclusion)

5 (0.8)

3 (0.5)

Transitional
Carcinoma
(Brenner)

5 (0.8)

2 (0.3)

Prior anthracycline
treatment

38 (6.1)

36 (5.9)

Time from initial
diagnosis to
randomization,
median (range),
months

24.25 (6.6, 169.3)

25.17 (2.5, 230.4)

Data are presented as No. (%) unless otherwise specified.
Abbreviation: PLD, pegylated liposomal doxorubicin.

3.4
3.4.1

|

Cardiac safety results

|

Trabectedin monotherapy (T)

In the pooled analysis of T, 110 (11.2%) patients who received ≥1 trabectedin dose experienced a cTEAE (Table S6).
cTEAEs reported for ≥1% of trabectedin-
treated patients
included tachycardia (3.1%), palpitations (1.5%), LVEF
decrease (1.3%), sinus tachycardia (1.0%), and congestive
cardiac failure (1.0%). Median time from the first dose of
study drug to the onset of first occurrence of a cTEAE for
trabectedin-treated patients was 40 days. For 65% of patients with cTEAE, the event was reported as resolved, with
a median time to resolution of 8 days. Thirty-seven (3.8%)
trabectedin-
treated patients experienced a Grade 3 or 4
cTEAE (Table S7). Cardiac-related serious TEAEs (SAEs)
were reported in 36 (3.7%) trabectedin-treated patients (Table
S8); those most frequently reported (≥5 patients) included:
congestive cardiac failure (0.8%), pulmonary edema (0.6%),
ejection fraction decreased (0.5%), cardiac failure (0.5%),

3570
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and atrial fibrillation (0.5%). Six (0.6%) trabectedin-treated
patients experienced a cTEAE leading to death (Table S9).

3.4.2

|

Unique study features

In the phase 3 study comparing trabectedin versus dacarbazine (SAR-3007), cTEAEs were reported for 58 (15.3%)
trabectedin patients and 25 (14.5%) dacarbazine patients;
however, cardiac failure (5.0% vs. 2.3%), cardiomyopathy (3.7% vs. 2.3%), and heart failure (2.9% vs. 0.6%) were
higher with trabectedin. Furthermore, the median cumulative prior anthracycline dose was greater in the trabectedin
group (329.75 mg/m2) compared to the dacarbazine group
(180.00 mg/m2), which should also be taken into consideration. Among patients with a cTEAE, more patients in the
trabectedin group (39 [67.2%] of 58) received a prior cumulative anthracycline dose ≥300 mg/m2 compared with the
dacarbazine group (10 [40.0%] of 25). Median time from the
first dose of study drug to the onset of first occurrence of a
cTEAE was twice as long in the trabectedin group compared
with the dacarbazine group (46 days vs. 23 days); however,
the median time to resolution was twice as long in the trabectedin group (8 days vs. 4 days). In terms of prior anthracycline
exposure among patients with a significant decrease in LVEF
from baseline and for whom dose information was reported,
prior cumulative anthracycline dose of ≥300 mg/m2 was reported in 22/34 (64.7%) in the trabectedin group compared
with 7/11 (63.6%) patients in the dacarbazine group.

3.4.3

|

Trabectedin in combination with PLD

cTEAEs were reported for 78 (12.6%) patients in the
trabectedin+PLD group and 34 (5.6%) patients in the PLD

monotherapy group; most commonly reported cTEAE was
LVEF decrease (7.8% vs. 4.2%, respectively). Within these
SMQ/HLGTs, palpitation was the only cTEAE reported with
at least a 2% greater incidence in the trabectedin+PLD group
compared with the PLD monotherapy group (3.2% vs. 1.0%)
(Table S10).
Kaplan-Meier analyses showed an increased risk of cTEAEs with trabectedin+PLD compared with PLD monotherapy (Figure 1). Cumulative incident rate curves separated
early and remained separated throughout treatment. Median
time from first study dose to the onset of first occurrence of
cTEAE was shorter with trabectedin+PLD (57 days) compared with PLD monotherapy (98 days), while most patients
in both groups had similar resolutions of cTEAEs (57.1% and
55.9%) and time to resolution (8 days). However, while Grade
3 or 4 cardiac-related events were reported more frequently
with trabectedin+PLD versus PLD monotherapy (14 [2.3%]
vs. 4 [0.7%] patients; Table S11); no cTEAEs were reported
with an incidence of ≥1% in either group. Last, cardiac-
related SAEs were reported more frequently with trabectedin+PLD (11 [1.8%]) vs. PLD monotherapy (3 [0.5%]) (Table
S12). Congestive heart failure was quite low in both the combination (3 [0.5%]) and monotherapy groups (1 [0.2%]).

3.4.4

|

Unique study features

In OVA-
301, fewer patients with a significant decrease
from baseline in LVEF in the trabectedin+PLD group had
a cardiovascular medical history compared with the PLD
monotherapy group (23.8% vs. 52.6%). In OVC-3006, median cumulative PLD dose for patients with a cTEAE was
lower with trabectedin+PLD treatment compared with PLD
monotherapy (180.78 vs. 329.67 mg/m2). Median cumulative anthracycline dose of ≥300 mg/m2 was reported in 11/43

F I G U R E 1 Cumulative Incidence
of Cardiac-Related Adverse Events Over
Treatment Duration for Treated Patients
(Pooled Studies ET743-OVC-3006 and
ET743-OVA-301). PLD, pegylated
liposomal doxorubicin
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(25.6%) in trabectedin+PLD patients with a cTEAE compared to 17/23 (73.9%) PLD monotherapy patients.
In OVC-3006, the median time from first dose of drug to
the onset of first occurrence of a cTEAE was shorter with
trabectedin+PLD compared with PLD monotherapy (68 days
vs. 169 days); however, the median time to resolution was
longer with PLD monotherapy group compared with trabectedin+PLD (29 days vs. 16 days). Median cumulative PLD
dose for patients having significant decreases from baseline
in LVEF was lower in the trabectedin+PLD group compared
with the PLD monotherapy group (149.39 vs. 251.25 mg/
m2). In addition, median cumulative anthracycline doses of
≥300 mg/m2 were associated with a significant decrease
from baseline in LVEF; this was reported in 3/19 (15.8%) trabectedin+PLD and 5/10 (50.0%) PLD monotherapy patients.

3.5
3.5.1

|

Multivariate analyses

|

Trabectedin monotherapy

Trabectedin-
treated patients who experienced a cTEAE
were generally older (18.4% aged ≥65 years vs. 9.6% aged
<65 years). Results from multivariate analyses of cTEAEs
when controlling for potential risk factors are presented in

|
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Figure 2. These showed that patients aged ≥65 years and
those with cardiovascular medical history had an increased
risk of cTEAEs. The effect of cumulative anthracycline dose
of ≥300 versus <300 mg/m2 and baseline LVEF <lower
limit of normal (LLN) versus ≥LLN, however, could not
be evaluated in the ten phase 2 studies due to differences in
study designs.

3.5.2

|

Trabectedin in combination with PLD

In the multivariate analyses, when controlling for potential risk factors, results showed that patients receiving
trabectedin+PLD were at increased risk for experiencing a
cTEAE compared with PLD monotherapy (risk ratio [RR]
2.70; 95% CI: 1.75–4.17; p < 0.0001). Furthermore, patients with a history of prior cardiac medication use who received trabectedin+PLD versus PLD were also at increased
risk of experiencing cTEAEs (RR 1.88; 95% CI: 1.16–3.05;
p = 0.010). Patients with a cumulative anthracycline dose of
≥300 mg/m2 who received trabectedin+PLD in the OVC-
3006 and OVA-301 trials were at increased risk for a significant decrease in LVEF compared with patients who received
PLD monotherapy (RR 0.54; 95% CI: 0.30–0.99; p = 0.046)
(Figure 3).

F I G U R E 2 Multivariate Analysis on Incidence of Cardiac-Related TEAEs (Logistic Regression) for Treated Patients (Trabectedin –Pooled
Phase 2 and 3 Studies). Dependent variable: incidence of cardiac-related TEAEs. CI, confidence interval; TEAEs, treatment-emergent adverse
events

F I G U R E 3 Multivariate Analysis on
Incidence of Significant LVEF Decrease
(Logistic Regression) for Treated Patients
(Pooled Studies OVC-3006 and OVA-301).
Dependent variable: incidence of significant
LVEF decrease. CI, confidence interval;
LVEF, left ventricular ejection fraction;
PLD, pegylated liposomal doxorubicin

3572
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Trabectedin was developed based on its novel chemical
structure and promising preclinical activity in several types
of human tumors. The development program focused on
STS3 and ROC4,5 in which trabectedin was active at very
low concentrations in both preclinical models and clinical
trials.1 Trabectedin binds to the N2 position of guanine
in the minor groove of DNA and bends the helix toward
the major groove, a unique property in the class of DNA-
binding agents; it triggers a cascade of events affecting
several transcription factors, DNA-binding proteins, and
DNA-repair pathways (e.g., transcription-coupled NER),
resulting in slowed progression through S and G2/M phases
and p53-independent apoptosis. Trabectedin also prevents
the binding of translocation-related oncogenic fusion proteins to DNA promoter regions, thereby interfering with
the function of proteins that contribute to the malignant
phenotype and tumor progression.6–9
PLD is doxorubicin hydrochloride encapsulated in
STEALTH® liposomes for intravenous administration. PLD
was granted approvals for advanced ovarian cancer in June
1999 and October 2000 in the United States and European
Union, respectively. As with any anthracycline, PLD can
cause myocardial damage, including congestive heart failure,
as the total cumulative dose of doxorubicin hydrochloride approaches 550 mg/m2. In a clinical study of 250 patients with
advanced cancer who were treated with PLD, the risk of cardiotoxicity was 11% when the cumulative anthracycline dose
was 450 to 550 mg/m2.10
This is the most comprehensive analysis of cardiac safety
in the setting of trabectedin administration from clinical trial
data including more than 1600 patients. Strengths include
pooled analyses of one phase 3 trial and ten phase 2 trials of
T in STS and two phase 3 trials of trabectedin in combination
with PLD for ROC. Limitations include patient heterogeneity and varying dosing, scheduling, and infusion times for T
(1.5 mg/m2 q3wk; 24 h) compared with PLD combination
therapy (trabectedin 1.1 mg/m2 q3wk; 3 h). The authors recognize that cardiac adverse events with diverse etiologies
make it difficult to ascribe the outcomes to trabectedin alone
or identify specific causal mechanisms. Cardiotoxicity may
be mediated by multiple mechanisms including damage from
prior cardiotoxic therapies (anthracyclines), preexisting cardiovascular comorbidities, and the alkylating MOA among
others. Last, the retrospective nature of data collection and
other events, such as sepsis (that could contribute to cardiac
events) are additional limitations.
In phase 3 SAR-3007 study3, no difference in the overall
incidence rate of any-grade cTEAEs was observed between
trabectedin-and dacarbazine-treated patients. Multivariate
analysis of safety data (data not shown) indicated that cumulative anthracycline dose of ≥300 mg/m2 and baseline LVEF
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<LLN were risk factors for the development of cTEAEs in
STS. In pooled analyses, only age ≥65 years and cardiovascular medical history were associated with an increased risk
of cTEAEs. This difference could be attributed to variability
in patient populations, pretreatment history, and consistent
baseline LVEF testing in the ten phase 2 studies compared
with SAR-3007. In summation, cardiac safety signals observed with T may be, in part, due to the history of prior or
concurrent therapy with an anthracycline, known for potential short-and long-term cardiotoxicity, and longer median
duration of treatment for patients receiving trabectedin.
In OVA-301 and OVC-3006, patients in the trabectedin+PLD groups experienced cTEAEs at a higher incidence,
regardless of toxicity grade, compared with PLD monotherapy patients. In OVA-301, multivariate analyses indicated an
increased risk of cTEAEs among patients in the trabectedin+PLD group compared with PLD monotherapy (data not
shown). In OVC-3006, however, a cumulative anthracycline
dose of ≥300 mg/m2 and prior cardiac medication use were
also identified as independently associated with increased
risk of cTEAEs (data not shown). Differences between the
two studies may be attributed to enrollment criteria for each
study. Inclusion criteria for OVC-3006 differed from OVA-
301 in that patients were allowed to have received two prior
lines versus one line of chemotherapy for ROC, and prior
PLD combination therapy was also allowed.
Ultimately, these data suggest that some patients receiving T after prior therapy with anthracyclines are at risk
for cTEAEs, which may be serious in a small number. The
overall risk of fatal events is relatively low but appears to be
higher for patients with existing myocardial dysfunction (abnormal LVEF) or prior cardiovascular medical history. In the
setting of STS, the available data support recommendations
to assess LVEF by echocardiogram or multigated acquisition
radionuclide scan before the initiation of trabectedin and at
two-to three-month intervals thereafter until trabectedin is
discontinued, particularly for patients with prior cardiovascular disease. Additionally, when using trabectedin in combination with PLD for ROC, cumulative anthracycline dose
≥300 mg/m2 and prior cardiac medication may increase the
risk of cTEAEs if prior lines of therapy involved PLD.
In conclusion, as with any systemic cytotoxic therapy,
benefit versus risk should be carefully considered when instituting treatment with trabectedin in patients with few other
treatment options and with risk factors for developing cTEAEs. In consultation with a cardiologist or cardio-oncology
service, baseline cardiovascular risk should be comprehensively assessed before commencing treatments with cardiotoxic potential as noted above.11,12 Cardiotoxicity risk
can be minimized by primary prevention strategies; signs
and symptoms of myocardial toxicity including decreases
in LVEF should be assessed routinely as described above.
Dose reductions or temporary or permanent discontinuation
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of trabectedin should be considered when serious cTEAEs
occur. Once the decision is made that benefits of trabectedin
therapy outweigh risk, patients (and caregivers) should be
supported throughout treatment with a personalized surveillance program to minimize cTEAE risk and promptly address
when cTEAEs do occur.
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